Maravai LifeSciences (MRVI) Expected to Release Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.0563) per share and revenue of $43.56 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. The business had revenue of $51.44 million during the quarter, compared to analyst estimates of $48.67 million. On average, analysts expect Maravai LifeSciences to post ($0.18) EPS for the current fiscal year and ($0.13) EPS for the next fiscal year.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $7.81 on Monday. Maravai LifeSciences has a 52 week low of $2.55 and a 52 week high of $9.42. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -15.02 and a beta of 0.61. The stock has a 50-day moving average price of $7.50 and a 200 day moving average price of $5.24.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MRVI shares. Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Friday, August 7th. TD Cowen started coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a “buy” rating and a $9.00 price objective on the stock. UBS Group lifted their price objective on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Finally, Wall Street Zen lowered Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.38.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.